Systematic Pan-Cancer Analysis Identifies CDK1 as an Immunological and Prognostic Biomarker

Figure 1

Expression levels of the CDK1 gene in different tumors and pathological stages. (a) Increase or decrease in the CDK1 levels in datasets of different cancers compared to the CDK1 levels in normal tissues in the Oncomine database. (b) CDK1 expression levels in different tumor types from the TCGA database were analyzed by TIMER2.0 (, , ). (c) Comparison of CDK1 expression levels between tumor tissues from the TCGA database and normal tissues from the GTEx database (, , ). (d) Based on the CPTAC dataset, the expression levels of total CDK1 protein were analyzed in normal and primary tissues of breast cancer, colon cancer, clear cell kidney cancer, and UCEC (). (e) Correlations between CDK1 expression and tumor stage in BRCA, COAD, LUAD, and LUSC patients (Log2 (TPM + 1) was applied for log scale).

(a)

(b)

(c)

(d)

(e)